Boxwood Merger Corp. (BWMC) Adjourns Vote to February 10th
by Kristi Marvin on 2020-02-06 at 11:29pm

This afternoon, Boxwood Merger Corp. (BWMC), which was originally scheduled to hold their shareholder vote today to complete their combination with Atlas Intermediate Holdings LLC, adjourned their meeting for the fourth time.  The new vote date is now scheduled for Monday, February 10th.

Boxwood most recently adjourned their shareholder vote on January 30th, to today (February 6th) citing, “Based on positive investor feedback to the financing arrangements announced yesterday in support of Boxwood’s proposed business combination (the “business combination”) with Atlas Intermediate Holdings LLC (“Atlas”), Boxwood is adjourning the special meeting to provide investors with additional time to consider the now fully-financed business combination.” So further adjourning to Monday, February 10th, is interesting because that only gives Boxwood two additional days now to secure their vote.  That’s a very short amount of time.  However, it does sort of indicate that their previous financing changes may not have gotten the traction they were hoping for, so it’s not totally outside the realm of possibility that they adjourn for a fifth time.

Plus, keep in mind that Boxwood doesn’t expire until November 20th, 2020.  However, as we’ve seen with TKKS, you really don’t want to give shareholders too much time to change their minds by adjourning two or three weeks out, so it appears Boxwood is looking to wrap this up quickly.  Only two days out also means we won’t see any gyrations in the share price where it zooms back up to estimated cash in trust value (again, like we saw with TKK Symphony’s share price) since there is no time for the share to be bought and sold ahead of a new redemption deadline, which is typically two days ahead of a shareholder vote (which may have been the point of only adjourning two days).

All told, Boxwood’s recent additional financing, which includes $155 million from GSO Capital Partners, the credit arm of Blackstone (“GSO”), plus an increased equity rollover of up to $50 million from Bernhard Capital Partners AND a debt commitment letter from Macquarie and Natixis, means there are a lot of big names guarding the hoop on this transaction, so some last minute horse-trading in order to get the deal done is always a possibility.  However, if Boxwood needs to adjourn for a fifth time on Monday…well, then we’ll know they have some much bigger issues.

 

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved